Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 1

Status

Completed 6Unknown 1

Sponsor Class

INDUSTRY 6OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2Thoracic 1Plasma cell 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasms 2Solid Tumors 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × INDUSTRY × LCL161 × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Novartis

Phase 1 Completed
26 enrolled
Plasma cell

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

NCT01240655 2020-12-19

A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
76 enrolled
Other solid neoplasm

Solid Tumors

NCT01968915 2020-12-19

Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
9 enrolled
Tumor-Agnostic

Neoplasms

NCT01617668 2016-10-17

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer

Novartis

Phase 2 Completed
209 enrolled 20 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01098838 2012-08-03

Safety and Efficacy of LCL161 in Patients With Solid Tumors

Novartis

Phase 1 Completed
71 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡